2025年6月,信达生物自主研发的新一代减重创新药信尔美(玛仕度肽注射液)获批上市,它是全球首个获批的GCG/GLP-1双靶减重降糖药物;10月,信达生物发布与武田制药达成全球战略合作的消息,受到行业高度关注。10月27日,南都N视频记者走访了信达生物在江苏苏州的生产基地。信达生物相关负责人向媒体重申了“出海”的决心、对自研减重药信尔美的信心,并通过与京东健康的合作展示出其药物销售渠道从传统线下...
Source Link2025年6月,信达生物自主研发的新一代减重创新药信尔美(玛仕度肽注射液)获批上市,它是全球首个获批的GCG/GLP-1双靶减重降糖药物;10月,信达生物发布与武田制药达成全球战略合作的消息,受到行业高度关注。10月27日,南都N视频记者走访了信达生物在江苏苏州的生产基地。信达生物相关负责人向媒体重申了“出海”的决心、对自研减重药信尔美的信心,并通过与京东健康的合作展示出其药物销售渠道从传统线下...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.